Skip to Main Content

WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve them on his own.

That’s looking increasingly likely after the White House’s concession on Thursday that it is abandoning its push for Congress to include major drug pricing provisions in its long-debated social spending bill. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment